<DOC>
	<DOCNO>NCT02182245</DOCNO>
	<brief_summary>The primary objective trial determine safety , tolerability , MTD BIBF 1120 add standard therapy carboplatin paclitaxel</brief_summary>
	<brief_title>Dose Escalation Study BIBF 1120 Patients With Advanced Gynaecological Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Genital Neoplasms , Female</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Nintedanib</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Female patient follow histologically confirm advanced gynaecological malignancy : epithelial ovarian cancer , endometrial carcinoma , uterine sarcoma , mixed Müllerian tumour , fallopian tube carcinoma , primary peritoneal carcinoma , cervical carcinoma vulvular carcinoma Metastatic disease locally advanced disease resectable curative intention Indication combination chemotherapy paclitaxel/carboplatin judge investigator Age 18 year old Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Life expectancy least 6 month Written inform consent consistent ICHGCP ( International Conference Harmonisation Good Clinical Practice ) guideline local requirement Participation another clinical study within past 4 week start therapy concomitantly study Radiotherapy within 4 week start therapy Chemotherapy , immunotherapy hormonal therapy ( exception hormonal replacement therapy ) within 4 week start therapy Patients germ cell tumour , early stage ovarian cancer ( Fédération Internationale de Gynécologie et d'Obstétrique [ FIGO ] stage IIIA ) , primary cervical cancer ( FIGO IIII ) , primary endometrial cancer ( FIGO IIII ) borderline tumours Patients know brain metastasis Symptomatic bowel obstruction know suspected malabsorption Patients pericardial effusion haemodynamically relevant Other malignancy diagnose within past 5 year ( nonmelanomatous skin cancer cervical carcinoma situ ) Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study medication History haemorrhagic thrombotic event ( include transient ischemic attack ) past 6 month Concurrent therapeutic anticoagulation antiplatelet therapy ( except chronic low dose daily acetylsalicylic acid &lt; 300 mg ) Major injury surgery within past 3 week , plan surgical procedure trial , incomplete wound heal Known hypersensitivity paclitaxel , carboplatin , BIBF 1120 excipients vehicle polyoxyethylated castor oil Clinically significant peripheral polyneuropathy ( &gt; CTCAE grade 1 ) precludes therapy paclitaxel Absolute neutrophil count ( ANC ) &lt; 1500/μL , platelet count &lt; 100000/μL , haemoglobin &lt; 9 mg/dL Total bilirubin &gt; 1.5 mg/dL ( 26 μmol/L ) , ALT ( Alanine aminotransferase ) and/or AST ( Aspartate aminotransferase ) &gt; 1.5 x upper limit normal ( ULN ) Serum creatinine &gt; 1.5 mg/dL ( &gt; 132 μmol/L ) Persistent gross haematuria Pregnancy breast feed Women childbearing potential sexually active unwilling use medically acceptable method contraception ( oral contraceptive , diaphragm spermicide , intrauterine device , condom spermicide ) Known suspect active drug alcohol abuse</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>